What is NTRB's earnings growth forecast for 2027-2027?
(NASDAQ: NTRB) Nutriband's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,472.81%.
Nutriband's earnings in 2026 is -$34,592,177.
In 2027, NTRB is forecast to generate $18,006,652 in earnings, with the lowest earnings forecast at $17,300,509 and the highest earnings forecast at $18,536,259.
What is NTRB's revenue growth forecast for 2027-2027?
(NASDAQ: NTRB) Nutriband's forecast annual revenue growth rate of 4,171.48% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.75%, and it is also forecast to beat the US market's average forecast revenue growth rate of 176.46%.
Nutriband's revenue in 2026 is $2,278,321.
In 2027, NTRB is forecast to generate $1,184,835,264 in revenue, with the lowest revenue forecast at $1,138,375,910 and the highest revenue forecast at $1,219,679,779.
What is NTRB's forecast return on assets (ROA) for 2027-2027?
(NASDAQ: NTRB) forecast ROA is 213.88%, which is higher than the forecast US Biotechnology industry average of -9.06%.
What is NTRB's Earnings Per Share (EPS) forecast for 2027-2027?
(NASDAQ: NTRB) Nutriband's current Earnings Per Share (EPS) is -$3.07. In 2027, NTRB's EPS is forecast to hit $1.48 (min: $1.42, max: $1.52).
What is NTRB's forecast return on equity (ROE) for 2027-2027?
(NASDAQ: NTRB) forecast ROE is 238.53%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.